These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38158497)

  • 1. Factors Affecting Recurrence and Survival for Patients with High-Risk Stage II Melanoma.
    Dedeilia A; Lwin T; Li S; Tarantino G; Tunsiricharoengul S; Lawless A; Sharova T; Liu D; Boland GM; Cohen S
    Ann Surg Oncol; 2024 Apr; 31(4):2713-2726. PubMed ID: 38158497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.
    Tan L; Sandhu S; Lee RJ; Li J; Callahan J; Ftouni S; Dhomen N; Middlehurst P; Wallace A; Raleigh J; Hatzimihalis A; Henderson MA; Shackleton M; Haydon A; Mar V; Gyorki DE; Oudit D; Dawson MA; Hicks RJ; Lorigan P; McArthur GA; Marais R; Wong SQ; Dawson SJ
    Ann Oncol; 2019 May; 30(5):804-814. PubMed ID: 30838379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.
    Zager JS; Gastman BR; Leachman S; Gonzalez RC; Fleming MD; Ferris LK; Ho J; Miller AR; Cook RW; Covington KR; Meldi-Plasseraud K; Middlebrook B; Kaminester LH; Greisinger A; Estrada SI; Pariser DM; Cranmer LD; Messina JL; Vetto JT; Wayne JD; Delman KA; Lawson DH; Gerami P
    BMC Cancer; 2018 Feb; 18(1):130. PubMed ID: 29402264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor Mitotic Rate and Association with Recurrence in Sentinel Lymph Node Negative Stage II Melanoma Patients.
    Laks S; Meyers MO; Deal AM; Frank JS; Stitzenberg KB; Yeh JJ; Thomas NE; Ollila DW
    Am Surg; 2017 Sep; 83(9):972-978. PubMed ID: 28958277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymph node ratio has impact on relapse and outcome in patients with stage III melanoma.
    Tas F; Erturk K
    Int J Clin Oncol; 2019 Jun; 24(6):721-726. PubMed ID: 30788673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma.
    Amaral TMS; Hoffmann MC; Sinnberg T; Niessner H; Sülberg H; Eigentler TK; Garbe C
    Eur J Cancer; 2020 Jan; 125():38-45. PubMed ID: 31838403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic features correlated with paradoxical outcomes in stage IIC versus IIIA melanoma patients.
    Tan SY; Najita J; Li X; Strazzulla LC; Dunbar H; Lee MY; Seery VJ; Buchbinder EI; Tawa NE; McDermott DF; Lee SJ; Atkins MB; Kim CC
    Melanoma Res; 2019 Feb; 29(1):70-76. PubMed ID: 30169431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective observational study of primary cutaneous malignant melanoma patients treated with excision only compared with excision biopsy followed by wider local excision.
    McKenna DB; Lee RJ; Prescott RJ; Doherty VR
    Br J Dermatol; 2004 Mar; 150(3):523-30. PubMed ID: 15030337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients.
    Lee JH; Saw RP; Thompson JF; Lo S; Spillane AJ; Shannon KF; Stretch JR; Howle J; Menzies AM; Carlino MS; Kefford RF; Long GV; Scolyer RA; Rizos H
    Ann Oncol; 2019 May; 30(5):815-822. PubMed ID: 30860590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationships between survival and real-world recurrence-free survival or distant metastasis-free survival among patients with completely resected stage IIB or IIC melanoma.
    Samlowski W; Silver MA; Hohlbauch A; Zhang S; Fukunaga-Kalabis M; Krepler C; Wang Y; Sruti I; Jiang R
    Melanoma Res; 2024 Aug; 34(4):326-334. PubMed ID: 38814728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor mitotic rate added to the equation: melanoma prognostic factors changed? : a single-institution database study on the prognostic value of tumor mitotic rate for sentinel lymph node status and survival of cutaneous melanoma patients.
    Speijers MJ; Bastiaannet E; Sloot S; Suurmeijer AJ; Hoekstra HJ
    Ann Surg Oncol; 2015 Sep; 22(9):2978-87. PubMed ID: 25605514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test.
    Hsueh EC; DeBloom JR; Lee J; Sussman JJ; Covington KR; Middlebrook B; Johnson C; Cook RW; Slingluff CL; McMasters KM
    J Hematol Oncol; 2017 Aug; 10(1):152. PubMed ID: 28851416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic role of mitotic rate in cutaneous malignant melanoma: Evidence from a multicenter study on behalf of the Italian Melanoma Intergroup.
    Patuzzo R; Mattavelli I; Gallino G; Galeone C; Valeri B; Mocellin S; Del Fiore P; Ribero S; Mandalà M; Tauceri F; Lombardo M; Maurichi A;
    Cancer; 2023 Aug; 129(15):2331-2340. PubMed ID: 37162404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and pathologic factors associated with distant metastasis and survival in patients with thin primary cutaneous melanoma.
    Murali R; Haydu LE; Long GV; Quinn MJ; Saw RP; Shannon K; Spillane AJ; Stretch JR; Kefford RF; Thompson JF; Scolyer RA
    Ann Surg Oncol; 2012 Jun; 19(6):1782-9. PubMed ID: 22350600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma of the ear: prognostic factors and surgical strategies.
    Jahn V; Breuninger H; Garbe C; Moehrle M
    Br J Dermatol; 2006 Feb; 154(2):310-8. PubMed ID: 16433802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapse patterns in patients with local and regional cutaneous melanoma.
    Tas F; Erturk K
    Clin Transl Oncol; 2019 Apr; 21(4):412-419. PubMed ID: 30182208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of a 31-gene expression profile for predicting outcomes in patients with primary cutaneous melanoma referred for sentinel node biopsy.
    Arnot SP; Han G; Fortino J; Han D; Fowler G; Vetto JT
    Am J Surg; 2021 Jun; 221(6):1195-1199. PubMed ID: 33773750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early-stage non-Spitzoid cutaneous melanoma in patients younger than 22 years of age at diagnosis: long-term follow-up and survival analysis.
    Stanelle EJ; Busam KJ; Rich BS; Christison-Lagay ER; Dunkel IJ; Marghoob AA; Halpern A; Coit DG; La Quaglia MP
    J Pediatr Surg; 2015 Jun; 50(6):1019-23. PubMed ID: 25819019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
    Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
    Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.
    Corrie PG; Marshall A; Nathan PD; Lorigan P; Gore M; Tahir S; Faust G; Kelly CG; Marples M; Danson SJ; Marshall E; Houston SJ; Board RE; Waterston AM; Nobes JP; Harries M; Kumar S; Goodman A; Dalgleish A; Martin-Clavijo A; Westwell S; Casasola R; Chao D; Maraveyas A; Patel PM; Ottensmeier CH; Farrugia D; Humphreys A; Eccles B; Young G; Barker EO; Harman C; Weiss M; Myers KA; Chhabra A; Rodwell SH; Dunn JA; Middleton MR; ; Nathan P; Lorigan P; Dziewulski P; Holikova S; Panwar U; Tahir S; Faust G; Thomas A; Corrie P; Sirohi B; Kelly C; Middleton M; Marples M; Danson S; Lester J; Marshall E; Ajaz M; Houston S; Board R; Eaton D; Waterston A; Nobes J; Loo S; Gray G; Stubbings H; Gore M; Harries M; Kumar S; Goodman A; Dalgleish A; Martin-Clavijo A; Marsden J; Westwell S; Casasola R; Chao D; Maraveyas A; Marshall E; Patel P; Ottensmeier C; Farrugia D; Humphreys A; Eccles B; Dega R; Herbert C; Price C; Brunt M; Scott-Brown M; Hamilton J; Hayward RL; Smyth J; Woodings P; Nayak N; Burrows L; Wolstenholme V; Wagstaff J; Nicolson M; Wilson A; Barlow C; Scrase C; Podd T; Gonzalez M; Stewart J; Highley M; Wolstenholme V; Grumett S; Goodman A; Talbot T; Nathan K; Coltart R; Gee B; Gore M; Farrugia D; Martin-Clavijo A; Marsden J; Price C; Farrugia D; Nathan K; Coltart R; Nathan K; Coltart R
    Ann Oncol; 2018 Aug; 29(8):1843-1852. PubMed ID: 30010756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.